Avistone Pharmaceuticals Secures $200 Million Strategic Investment From Vivo Capital, Bain Capital And Primavera Capital

Dec 08, 2021•almost 4 years ago

Amount Raised

$200 Million

BeijingTravel And Tourism

Description

Avistone Pharmaceuticals (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced it has received a strategic investment of more than $200 million led by Vivo Capital with participation from Bain Capital and Primavera Capital (collectively the “Investor Group”). The investment will support the combination of Avistone with Pearl Biotechnology Co. Ltd. to create a fully-integrated targeted oncology platform that will address unmet patient needs globally.

Company Information

Company

Avistone Biotechnology

Location

Beijing, Beijing, China

About

Avistone is a clinical-stage biotechnology company based in Beijing, China, focusing on researching and developing innovative therapies for patients with significant unmet medical needs globally. The company’s core team comprises experienced drug design and clinical development experts, supported by a scientific advisory committee that includes internationally renowned KOLs. Avistone has an extensive pipeline of targeted therapies for molecular drivers of cancer, including two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Avistone Pharmaceuticals Secures $200 Million Strategic Investment From Vivo Capital, Bain Capital And Primavera Capital

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information